DS
ALXN

David Shaw’s Alexion Pharmaceuticals ALXN Stock Holding History

David Shaw’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,900
Closed -$2.83M – 3968
2019
Q1 		$2.83M Buy
20,900
+10,000
+92% +$1.24M ﹤0.01% 1925
2018
Q4 		$1.06M Buy
+10,900
New +$1.29M ﹤0.01% 2613
2018
Q1 		– Sell
-15,000
Closed -$1.79M – 3879
2017
Q4 		$1.79M Buy
+15,000
New +$1.83M ﹤0.01% 2215
2016
Q1 		– Sell
-49,300
Closed -$9.4M – 3894
2015
Q4 		$9.4M Hold
49,300
– – 0.01% 999
2015
Q3 		$7.71M Hold
49,300
– – 0.01% 1119
2015
Q2 		$8.91M Hold
49,300
– – 0.01% 1085
2015
Q1 		$8.54M Sell
49,300
-24,400
-33% -$4.42M 0.01% 1063
2014
Q4 		$13.6M Sell
73,700
-38,200
-34% -$7.08M 0.02% 913
2014
Q3 		$18.6M Sell
111,900
-1,600
-1% -$263K 0.02% 741
2014
Q2 		$17.7M Buy
113,500
+4,200
+4% +$663K 0.02% 759
2014
Q1 		$16.6M Buy
109,300
+9,700
+10% +$1.54M 0.02% 750
2013
Q4 		$13.3M Buy
99,600
+37,100
+59% +$4.45M 0.02% 934
2013
Q3 		$7.26M Buy
62,500
+40,000
+178% +$4.39M 0.01% 1276
2013
Q2 		$2.08M Buy
+22,500
New +$2.17M ﹤0.01% 2075

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

David Shaw's ALXN Position: Q3 2021 in Review

David Shaw sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,241,928 shares — an estimated $228M sold.

David Shaw first reported a position in ALXN in Q2 2013 and held it in 30 quarters. The position peaked at $228M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • David Shaw reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 1,241,928 Alexion Pharmaceuticals shares in Q3 2021, an estimated $228M.
  • David Shaw first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • David Shaw's Alexion Pharmaceuticals position peaked at $228M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.